Newsroom

2024

• Mar. 12, 2024
  Sumitomo Pharma Announces Availability of ORGOVYX^® (relugolix) in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer

• Jan. 31, 2024
  Sumitomo Pharma and Pfizer Canada Announce Availability of MYFEMBREE^® in Canada

2023

• Oct. 23, 2023
  Sumitomo Pharma Announces Authorization in Canada of ORGOVYX^® (relugolix) for the Treatment of Men with Advanced Prostate Cancer

2023

• Oct. 19, 2023
  Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE^®

2017

• Jul. 21, 2017
  Sunovion's Latuda^® (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia

2014

• Jul. 11, 2014
  Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM™ (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy

2013

• Sep. 18, 2013
  Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance for Review of the New Drug Submission of eslicarbazepine acetate as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy

2012

• Sep. 17, 2012
  Sunovion Pharmaceuticals Canada Inc. Announces the Launch of Once-Daily LATUDA™ (lurasidone HCl) for the Treatment of Patients with Schizophrenia
• Jun. 15, 2012
  Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of Once-Daily LATUDA™ (lurasidone HCl) for the Treatment of Patients with Schizophrenia

2011

• Aug. 23, 2011
  Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia